Table 2

 Clinical outcomes of neuropsychiatric systemic lupus erythaematosus after anti-CD20 antibody treatment

PatientDose of rituximabOther treatments at study entry (mg)CNS manifestationsObjective NPSLE findings after treatmentDuration of remission (m)
Bet, betamethasone; BPRS, brief psychiatric rating scale; CNS, central nervous system; GCS, Glasgow Coma Scale; m-PSL, methylprednisolone; MRI, magnetic resonance imaging; NPSLE, neuropsychiatric systemic lupus erythaematosus; PET, 18FTG-positron emission tomography; PSL, prednisolone; SDS, self-rating depression scale; SPECT, single photon emission computed tomography. For other abbreviations, see table 1.
1375 mg/m2 day 1, 8Bet 1.0Consciousness disorder, seizure, psychosisComplete recovery (GCS 7–11→15/5 days)Improvement of SPECT22
2375 mg/m2 day 1, 15Bet 1.5Consciousness disorderImproved consciousnessNo follow-up data18
3375 mg/m2 day 1, 8Bet 1.0Consciousness disorder, seizureComplete recovery (GCS 3→14/2 days)No improvement in MRI and SPECT23
4375 mg/m2 day 1, 8m-PSL 20HeadacheResolution of headacheImproved IgG index (1.05 →0.84/4 w)29
5375 mg/m2 day 1, 8Bet 1.25Paresthesia of fingers, toes and left precordial-backResolution of paresthesiaImprovement of neck MRI7
6500 mg day 1, 8, 15, 22Bet 2.5Depressive state, insomniaImprovement of depressive stateImprovement of SPECT7
7500 mg day 1, 8, 15, 22Bet 1.25Paresis of both lower limbs, muscle weakness, depressive stateReduction of paresis, improvement of depressive state (SDS 58→50/2 w)Improvement of SPECT, improvement of IgG index (0.80 →0.72/3 m)14
81000 mg day 1, 15Bet 1.25, AZ 50Psychosis, cognitive dysfunctionImprovement of psychosis (BPRS 26→7/8 w)Improvement of SPECT11
9375 mg/m2 day 1PSL 45Consciousness disorder, psychosis, paresis of both lower limbs, neurological bladderComplete recoveryImprovement of PET and MRI, improved IgG index (0.98 →0.61/2 w)10
10375 mg/m2 day 1, 8Bet 3Consciousness disorder, hallucination, cataplexyComplete recoveryNo significant improvement in objective findings4